ProPhase Labs (PRPH -4.29%), a diversified consumer healthcare and diagnostics company, posted its second-quarter 2025 results on August 13, 2025. The most notable news was a sharp shortfall in GAAP revenue, offset by a much narrower GAAP loss per share compared to expectations. While the company reported an GAAP earnings per share (EPS) loss of $(0.11), this was better than the analyst consensus of $(0.15) GAAP. Revenue (GAAP) was $1.2 million, far under the estimated $3.55 million (GAAP). Despite progress on margins and debt reduction, overall performance in the quarter reflects a company still operating at a diminished scale, with ongoing liquidity pressures and continued core operating losses.
| Metric | Q2 2025 | Q2 2025 Estimate | Q2 2024 | Y/Y Change |
|---|---|---|---|---|
| EPS (GAAP) | $(0.11) | $(0.15) | $(0.29) | 62.1 % |
| Revenue (GAAP) | N/A | $3.55 million | $1.50 million | 136.7 % |
| Gross Profit (GAAP) | $0.73 million | N/A | N/A | |
| Adjusted EBITDA | $(0.81) million | $(4.83) million | 83.2 % | |
| Cash and Cash Equivalents | $0.17 million | N/A | $1.78 million* | N/A |
Source: Analyst estimates for the quarter provided by FactSet.
Business Background and Key Focus Areas
ProPhase Labs develops and markets over-the-counter health supplements and diagnostic tools. Its product lineup includes dietary supplements for consumer health and the BE-Smart™ esophageal cancer diagnostic test, and it has historically generated revenue from its Nebula Genomics whole genome sequencing business. The company is based in Garden City, New York, and previously grew through contract manufacturing, distribution, and a wide range of consumer products.
Recently, its focus has shifted toward tightening the business portfolio, improving cash flow, and pursuing high-margin areas. ProPhase has prioritized executing on insurance receivables recovery, preparing the BE-Smart™ diagnostic test for launch, and seeking a buyer for Nebula Genomics. Repaying debt and reducing operating expenses remain central to its near-term aims, with management highlighting the need for cost discipline and careful use of any new funds.
Quarter in Review: Financial and Strategic Developments
The company's $1.2 million reported GAAP revenue reflects a steep decline—down 20% year over year—and a major miss against expectations, as GAAP revenue of $1.2 million missed the analyst estimate of $3.55 million by 66.2%. Only the consumer products segment generated revenue in the quarter. The diagnostics segment produced no sales, marking a second consecutive year with zero diagnostics revenue. reflecting the company’s transition to a leaner operational structure.
Gross profit (GAAP) sharply improved from a loss of $(0.16) million in Q2 2024 to a profit, with gross margin (GAAP) rose to 58.9%. In its consumer products segment, margin reached 67.8%, up from 36.8% a year ago. The significant margin shift resulted from increased sales of consumer products with a better margin product mix. General and administrative expense (GAAP) fell by roughly one-third to $4.6 million compared to Q2 2024, and research and development (R&D) spend was cut to just $4,000 (GAAP). These actions narrowed the net loss from continuing operations to $4.47 million (GAAP), compared with a GAAP loss of $5.463 million in Q2 2024.
Balance sheet changes were highlighted by the completion of asset sales, most notably the divestiture of PMI and Pharmaloz Real Estate, which brought in $8.7 million in gains from the sale of PMI and Pharmaloz Real Estate and wiped out more than $20 million in debt and liabilities. Reducing merchant cash advance borrowings helped lessen ProPhase’s largest monthly cash outflows. Despite that progress, cash (GAAP) dwindled to just $0.17 million at quarter-end, and working capital deficit remained significant, though improved to $(1.1) million as of June 30, 2025.
On a non-GAAP basis, adjusted EBITDA (non-GAAP) improved to $(0.81) million from $(4.83) million the year before. This shows loss reduction through streamlining, though the business is not yet profitable. The company’s share count rose substantially to 41.54 million compared to 18.89 million in Q2 2024, mainly due to new financings that provided vital liquidity during the transition.
Updates on Major Initiatives and Segments
The BE-Smart™ esophageal pre-cancer diagnostic test represents a major strategic focus. This laboratory-developed test (LDT) received a new patent in August 2025, expanding its intellectual property base. A change in U.S. Food & Drug Administration enforcement policy for LDTs means ProPhase can advance BE-Smart’s commercialization more quickly, with management expecting the first patient tests later in the year. However, full-scale adoption will be a multi-year process, and the product has not yet generated revenue.
Within the genomics business, Nebula Genomics moved to breakeven operating status after exiting its lab operations, cutting staff, and trimming costs. The division’s genome sequencing database—described as one of the world’s largest—remains a potential asset. The company is actively pursuing a sale of Nebula, which has annualized revenue of around $5 million (as stated by management for DNA Complete and Nebula Genomics combined, current as of Q1 2025) and could see further upside if more marketing investment is made.
ProPhase is also engaged in insurance claims recovery through Crown Medical, seeking to collect past payments for earlier COVID and other diagnostic services. Management estimates up to $50 million could potentially be recovered in the second half of 2025, with $20.086 million currently recorded as accounts receivable (GAAP) as of Q2 2025. Efforts are ongoing, and if realized, the cash influx could fundamentally reshape the company’s financial picture.
A newly announced crypto treasury strategy allows for limited investment in digital assets such as Bitcoin. The board has stated that any share sales or new issuances will be tightly controlled, with a preference to use debt as a bridge until larger cash events—such as insurance collections or a sale of the genomics business—materialize. ProPhase Labs does not currently pay a dividend.
Looking Ahead
Management did not issue detailed forward financial guidance for the coming quarters or the full year. During the post-earnings conference call, leadership emphasized an expectation for multiple cash-generating events in the second half of fiscal 2025, including collections from insurance receivables and the potential sale of Nebula Genomics. The anticipated receipts from these efforts, if successful, could be substantial, but timing and amounts remain uncertain.
Until any of these events occur, investors will likely monitor the company’s ability to secure short-term bridge financing for ongoing operations, its progress on the commercial launch of BE-Smart™, potential asset sales, and any new developments in capital-raising or treasury strategy. Liquidity remains tight, and with losses continuing, successful execution on these future plans is critical for ProPhase’s reversal toward sustained growth and financial stability.
PRPH does not currently pay a dividend.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
